Loading…
No business profile yet.
Size ACRO Biomedical (6748.TWO) is a Taiwan Health Care company (Medical Specialties) with a market value of $347M, the 590th largest of 687 Taiwan companies the cockpit tracks. Shares closed at NT$160.00 on 6 Nov 2026.
Performance Over six months the shares gained 128.6%, against -9.6% for the median peer and -3.4% for the Taiwan market (cap-weighted) — highest of 20 in its peer set.
Growth Revenue grew 44.5% over the last twelve months (peer median +5.3%); the operating margin is -178.3% (peer median 4.2%).
Valuation It trades at 200.7× enterprise value to sales against a peer median of 4.2× (most expensive of 21).
Capital Return on invested capital runs 46.2 points below its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$52.8M | NT$38.3M | NT$44.2M | NT$51.1M | NT$27.6M |
| Revenue growth | — | -14% | -13% | +85% | — |
| Gross profit | NT$28.0M | NT$12.2M | NT$17.8M | NT$31.0M | NT$7.37M |
| EBITDA | -NT$78.2M | -NT$75.7M | -NT$51.2M | -NT$37.7M | -NT$53.6M |
| Net income | -NT$78.8M | -NT$82.7M | -NT$62.1M | -NT$41.4M | -NT$60.9M |
| Free cash flow | -NT$81.5M | -NT$61.8M | -NT$73.7M | -NT$68.6M | -NT$50.3M |
| Capital expenditure | NT$11.3M | NT$15.4M | NT$32.6M | NT$22.5M | NT$4.44M |
| Total debt | n/a | NT$10.6M | NT$15.8M | NT$21.7M | NT$11.8M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6748.TWO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -24.2% | -4.0% | 2nd lowest of 21 |
| 6-month return | +128.6% | -9.6% | highest of 20 |
| Distance from 52-week high | -48.4% | -30.0% | 8th lowest of 21 |
| Revenue growth (TTM) | +44.5% | +5.3% | 3rd highest of 21 |
| Operating margin | -178.3% | 4.2% | 3rd lowest of 21 |
| EV / Sales | 200.7× | 4.2× | most expensive of 21 |
| ROIC minus cost of capital | -46.2 pp | -4.2 pp | lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| ACRO Biomedical 6748.TWO | Taiwan | $347M | +129% | +45% | -178% | 200.7× | n/a | n/a |
| Embecta EMBC | United States | $351M | +70% | -8% | 26% | 1.6× | -19.9% | -0.1% |
| BioNote 377740.KS | South Korea | $343M | -10% | +13% | 16% | 0.8× | -19.8% | -28.5% |
| Chemclin Diagnostics 688468.SS | China | $342M | -23% | -14% | 6% | 6.2× | 31.9% | -4.5% |
| Shenzhen Bioeasy Biotechnology 300942.SZ | China | $352M | -27% | +12% | -2% | 8.1× | n/a | n/a |
| Orchestra BioMed OBIO | United States | $341M | +41% | +986% | -181% | 9.8× | n/a | n/a |
| Stratec SBS.DE | Germany | $341M | +41% | -3% | 3% | 1.6× | n/a | n/a |
| Peijia Medical 9996.HK | Hong Kong | $340M | -34% | +21% | -13% | 2.9× | n/a | n/a |
| Chongqing Xishan Science and Technology 688576.SS | China | $356M | -26% | -23% | -29% | 6.5× | n/a | n/a |
| CapsoVision CV | United States | $336M | -11% | +15% | -217% | 23.6× | n/a | n/a |
| Jiangsu Nanfang Medical 603880.SS | China | $336M | +4% | -7% | -15% | 4.7× | 22.5% | -10.9% |
| COLTENE CLTN.SW | Switzerland | $361M | +3% | -2% | 8% | 1.4× | 0.1% | -0.7% |
| IVF HARTMANN VBSN.SW | Switzerland | $364M | -5% | +7% | 14% | 1.1× | -12.7% | -1.3% |
| Star Sports Medicine 1609.HK | Hong Kong | $367M | -76% | +23% | 37% | 3.7× | -13.2% | +36.8% |
| Mobia Medical MOBI | United States | $373M | n/a | +105% | -145% | 6.4× | n/a | n/a |
| Tauns Laboratories 197A.T | Japan | $322M | -2% | -23% | 29% | 4.8× | n/a | n/a |
| Kontour (Xi'an) Medical Technology 688314.SS | China | $321M | -39% | +4% | 27% | 5.3× | 6.1% | +16.4% |
| Surgical Science Sweden SUS.ST | Sweden | $321M | +86% | +8% | 16% | 2.4× | 4.3% | +56.8% |
| Japan Eyewear 5889.T | Japan | $321M | -7% | +15% | 32% | 3.1× | -9.0% | +20.2% |
| Orthofix Medical OFIX | United States | $321M | -32% | +3% | -4% | 0.6× | n/a | n/a |
| Jiangsu Apon Medical Technology 300753.SZ | China | $376M | -27% | -15% | -10% | 8.0× | 22.4% | -5.1% |